Vaccine leader Amy is in the midst of a year of intensive product declaration, and good news has been spreading one after another. According to the company's announcement on December 19th, its new technology route of suspension cultured MDCK cell influenza vaccine and second-generation high-efficiency adsorption tetanus vaccine have successively obtained the "Drug Clinical Trial Approval Notice" from the National Medical Products Administration. This series of developments not only demonstrates the strong innovation and research capabilities of Emmy vaccines, but also opens up vast opportunities for the company's future performance growth.

On November 25th that AIM Vaccine announced that the company held an Investor Open Day on November 21st. CITIC Securities, Guotai Junan, Shenwan Hongyuan, Huaxin Securities, and 57 other securities firms and institutional investors, as well as some industry experts, visited AIM's modern production base in Ningbo to have discussions and exchanges with the management.

AIM Vaccine, which is accelerating the iteration and upgrade of rabies vaccines, has achieved new results in new product R&D. AIM Vaccine announced on November 17th that the company's independently developed serum-free iterative rabies vaccine has recently submitted a pre-application for market registration to the National Medical Products Administration.

On November 15th, the Center for Drug Evaluation, NMPA showed that the market registration of AIM Vaccine's developed 13-valent conjugate pneumonia vaccine was formally accepted. It is reported that AIM's 13-valent conjugate pneumonia vaccine adopts a single-carrier tetanus toxoid carrier technology route, which has higher yield compared to the diphtheria toxin carrier variant (CRM197) in the single-carrier protein route, and fewer production capacity factors compared to the dual-carrier route, possessing multiple competitive advantages.

Rabies vaccine giant AIM Vaccine announced on November 7th that the company's developed iterative high-efficacy human diploid cell rabies vaccine has submitted a clinical application to the Center for Drug Evaluation (CDE), NMPA. This means that AIM's strategic layout for the iteration and upgrading of rabies vaccines is accelerating its implementation. According to the announcement, AIM's iterative high-efficacy human diploid cell rabies vaccine demonstrates the iteration and upgrading of the product in many aspects.

AIM Vaccine announced on November 1st that the company's independently developed 13-valent conjugate pneumonia vaccine has submitted an application for drug market registration to the National Medical Products Administration. The group's wholly-owned subsidiary, AIM Persistence Biopharmaceutical Co., Ltd., has obtained the corresponding drug production license to produce this product. The launch of this vaccine is imminent, and after its launch, AIM will become an important global supplier of the 13-valent conjugate pneumonia vaccine, significantly enhancing the company's performance.